Objective: To investigate the pooled incidence or the prevalence of erectile dysfunction, and to assess the risk of erectile dysfunction in patients with atrial fibrillation. Methods: A systematic review was carried out in the MEDLINE, EMBASE and Cochrane databases from inception through January 2018 to identify: (i) studies that reported the incidence and/or prevalence of erectile dysfunction in atrial fibrillation patients; or (ii) studies that assessed the association between atrial fibrillation and erectile dysfunction. Pooled odds ratios and 95% confidence intervals were calculated using a random effects model. Results: Five observational studies (27 841 patients) were enrolled. The pooled estimated prevalence of erectile dysfunction in atrial fibrillation patients was 57% (95% confidence interval 50-64, I 2 = 0). A study showed an incidence of newly diagnosed erectile dysfunction in atrial fibrillation patients of 0.96% during the mean follow-up duration of 4.67 AE 3.20 years. There was a significant association of atrial fibrillation with an increased risk of erectile dysfunction, with a pooled odds ratio of 1.79 (95% confidence interval 1.44-2.23, I 2 = 0%). The data on the risk of atrial fibrillation development in patients with erectile dysfunction were limited. A study showed the comparable risk of atrial fibrillation in patients with erectile dysfunction (odds ratio 1.03, 95% confidence interval 0.67-1.5), when compared with those without erectile dysfunction. Conclusions: The present study suggests a significant association between erectile dysfunction and atrial fibrillation. The overall estimated prevalence of erectile dysfunction among atrial fibrillation patients is 57%. However, despite limited data, the current evidence suggests a low incidence of new erectile dysfunction in atrial fibrillation patients.
Introduction
ED is an inability to reach or maintain an erection to achieve sexual intercourse. 1 It is a very common problem that is found in 20-40% of men aged >20 years. 2 Treating testosterone deficiency in ED patients has been shown to potentially reduce cardiovascular mortality in patients without cardiovascular diseases. 3 Also, testosterone deficiency is considered as an independent risk factor for cardiovascular events. 3 In addition, ED is an important, but overlooked, problem that might put patients at risk of cardiovascular diseases. 4 Prior studies have shown that the presence of CAD, CKD, chronic obstructive pulmonary disease, DM, prior stroke and beta-blocker use is strongly related to ED. 5 Approximately 33 million people have AF worldwide. In the USA, this common heart rhythm disorder affects an estimated 2.7-6.1 million people, 6 and is expected to double by the year 2050. 7 Recently, ED has been increasingly recognized among patients with AF, and results in a significant impact on their quality of life. [8] [9] [10] However, the relationship between ED and AF remains unclear, with conflicting data from previous studies regarding the incidence and prevalence. [9] [10] [11] [12] [13] The aims of the present systematic review and meta-analysis were: (i) to investigate the pooled incidence or prevalence of ED; and (ii) to assess the risk of ED in AF patients.
Methods

Literature review and search strategy
The protocol for the present meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; noCRD42018086050). A systematic literature search of MEDLINE (1946 to January 2018), EMBASE (1988 to January 2018) and the Cochrane Database of Systematic Reviews (database inception to January 2018) was carried out to identify all original studies that investigated the incidence/ prevalence and the risk of ED in AF patients. The systematic literature review was undertaken independently by two investigators (RC and CT) applying the search approach that incorporated the terms of "ED" or "penile erection" or "orgasm" or "impotence" and "AF," which is provided in Appendix S1. No language limitation was applied. A manual search for conceivably relevant studies using references of the included articles was also carried out. The present study was carried out by the STROBE (reporting epidemiological studies) and the PRISMA statement, as described in Appendix S2.
Selection criteria
Eligible studies must be cohort, cross-sectional or case-control studies that assessed: (i) the incidence/prevalence of ED in AF patients; or (ii) the association between ED and AF. They must provide the estimated incidence, prevalence or effect estimates (OR, relative risks or hazard ratios with 95% CIs). Inclusion was not limited by study size. Retrieved articles were individually reviewed for their eligibility by the two investigators noted previously. Discrepancies were discussed and resolved by mutual consensus. The Newcastle-Ottawa quality assessment scale was used to appraise the quality of study for case-control studies and outcome of interest for cohort studies. The modified Newcastle-Ottawa scale was used for cross-sectional studies, as shown in Tables 1 and 2 .
Data abstraction
A structured data collecting form was utilized to derive the following information from each study including title, year of the study, name of the first author, publication year, country where the study was carried out, demographic and characteristic data of participants, methods used to identify AF, definitions of ED, adjusted effect estimates with 95% CI, and covariates that were adjusted in the multivariable analysis.
Statistical analysis
We used Comprehensive Meta-Analysis software (version 3.3.070; Biostat Inc, Englewood, NJ, USA) to analyze the data. Adjusted point estimates from each study were consolidated by the generic inverse variance approach of DerSimonian and Laird, which designated the weight of each study based on its variance. 14 In light of the high likelihood of between-study variance because of the different study populations and the variable definitions of ED, a random effects model was utilized to assess the pooled prevalence and OR with 95% CI for the association between ED and AF. Cochran's Q test and I 2 statistic were applied to determine the between-study heterogeneity. A value of I 2 0-25% represents insignificant heterogeneity, 26-50% represents low heterogeneity, 51-75% represents moderate heterogeneity and >75% represents high heterogeneity. 15 The presence of publication bias was evaluated by Egger's test.
16 Table 1 Main characteristics of the studies assessing the incidence or prevalence of ED in patients with AF Lin et al. 8 Wolf et al. 9 Yilmaz et al. 12 Platek et al. Selection (4) Comparability (2) Outcome (3) Selection (5) Comparability (0) Outcome (3) Selection (4) Comparability (2) Outcome (3) Selection (4) Comparability (0) Outcome (3)
Results
A total of 3374 potentially eligible articles were identified using our search strategy. After the exclusion of 3338 articles, as they were duplicated, case reports, correspondences, review articles, in vitro studies, animal studies or interventional studies, 36 articles remained for full-length review. Of these, 24 were excluded from the full-length review, as they did not report the outcome of interest, and six articles were excluded because they were descriptive studies without comparative analysis. Patient populations in two articles by Platek et al. 10 and Szyma nski et al. 17 were similar, and we included the study by Platek et al. 10 as it provided more details and updated data for this meta-analysis. Thus, the final analysis included five observational studies with 27 841 patients. [8] [9] [10] 12 The literature retrieval, review and selection process are shown in Figure 1 . The characteristics and quality assessment of the included studies are presented in Tables 1 and 2 . [8] [9] [10] 12 Definition of ED ED, based on ICD-9-CM, is diagnosed by the presence of suggestive symptoms characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity. 18 Most of our studies defined ED by self-questionnaires, which included the IIEF and SHIM questionnaires. [8] [9] [10] 12 These self-report surveys have many items focusing on erectile function and intercourse satisfactory, and provide excellent diagnostic correlation to define the presence and severity of ED. 19 IIEF-5 comprises of five questions that add up to a total score of 25, and the criteria for the diagnosis of ED were met with a score of ≤21.
19 Therefore, most of the studies used standard screening tools even without testosterone level data.
Prevalence and incidence of ED in patients with AF
Four studies evaluated the incidence or prevalence of ED in patients with AF, as shown in Table 1 . [8] [9] [10] 12 The pooled estimated prevalence of ED (three studies) in AF patients was 57% (95% CI 50-64; Fig. 2) . 9, 10, 12 There was no significant heterogeneity with I 2 of 0%. The data on the incidence of ED in AF patients were limited. One study showed the incidence of newly diagnosed ED in AF patients to be 0.96% during a mean follow-up duration of 4.67 AE 3.20 years. 8 
Association between AF and ED
The main characteristics of the studies assessing the association between ED and AF are shown in Table 2 . 8, 12, 13 Two studies evaluated the risk of ED in patients with AF, when compared with those without AF. 8, 12 There was a significant association of AF with an increased risk of ED, with a pooled OR of 1.79 (95% CI 1.44-2.23, I 2 = 0%; Fig. 3 ). The data on the risk of AF development in patients with ED were limited. A study with propensity score matching analysis showed comparable risk of AF in patients with ED (OR 1.03, 95% CI 0.67 -1.58), when compared with those without ED. 13 
Evaluation for publication bias
Funnel plots (Fig. S1 ) were used to evaluate for publication bias in the prevalence of ED in patients with AF. Because of the limited number of studies, as a rule of thumb, the power of the test is too low to differentiate chance from real asymmetry. 20 Egger's regression asymmetry test was carried out and showed no publication bias with P = 0.47 for analysis evaluating the prevalence of ED in patients with AF. Selection (4) Comparability (2) Outcome (3) Selection (4) Comparability (2) Outcome (3) Selection (4) Comparability (2) Outcome (3)
Discussion
In the present systematic review, we showed a significant association between AF and ED. Our study also showed the high prevalence of ED among patients with AF. However, the incidence of ED is disproportionately low in AF patients. There are several plausible explanations underlying the pathophysiology of AF-related ED (Fig. 4) potentially through thrombophilia state, embolization, endothelial dysfunction and systemic inflammation. 9, 10, 12 First, increased thromboembolic risks in AF patients can affect all vascular territory, leading to a higher prevalence of ED in this patient population. 5 Second, microthrombi embolization from the left atrium to the penile artery is also possible. 21 Third, increased plasma levels of prothrombotic substance, von Willebrand factor and soluble Eselectin are shown in all types of AF patients. 22 Endothelial dysfunction is well established in AF patients, and also puts them at higher risk of ED. 8 Fourth, in the past decade, scientific data support the idea that AF strongly relates to systemic inflammation and endothelial dysfunction, regardless of traditional stroke risk factors. Inflammation plays an important role in endothelial dysfunction in AF. 23 Activation of inflammatory 1544 were excluded due to duplications.
1794 articles were excluded based on title and abstract for clearly not fulfilling inclusion criteria on basis of type of article, study design, population or outcome of interest.
24 articles were excluded because they did not report the outcomes of interest.
6 articles were excluded because they were not observational studies.
An article was excluded (used the same patient population as one of included studies in final analysis).
Title and abstract reviewed for screening.
36 potentially relevant articles included for fulllength article review.
5 articles were identified.
Potentially relevant articles identified from search of MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews (n = 3374) Fig. 1 Outline of the search methodology used for the present study.
Study name Statistics for each study Event rate and 95% CI Fig. 2 Forest plots of included studies evaluating the prevalence of ED in patients with AF. Square data markers represent prevalence; horizontal lines represent the 95% CIs, with marker size reflecting the statistical weight of the study using random effects meta-analysis. A diamond data marker represents the overall prevalence and 95% CI.
cells and mediators during AF connect AF to vascular inflammation, dysfunction and a prothrombotic state. In addition, impaired acetylcholine-mediated blood flow and a decreased plasma nitrate level leads to impaired systemic blood flow and ED. 24 Finally, downregulation of vasodilatory substances and upregulation of angiotensin enzyme in an iatrogenic atrial tachycardia animal model also additively potentiate the prothrombotic effect. 22 Hence, multifactorial pathogenesis triggered by AF additively contributes to ED (Fig. 4) . 23, 25 ED is currently not included into factors that used by physician to initiate anticoagulation therapy in AF patients. As older age (>65 years) is one of the risk factors for stroke in AF, the ED population tends to have a higher risk of stroke for this reason. There is still a lack of data to define whether ED is an independent risk factor of stroke in AF. 5 Emerging evidence proposes the presence of OSAFED, so-called OSAFED syndrome. 9 More than one phenotype caused by a common risk factor, specifically the major role played by obesity, could be manifested in patients with this syndrome. 26 Wolf et al. carried out a study and recommended testing for occult OSA and ED in patients who were newly diagnosed with AF for early detection and treatment of this more common than expected syndrome. 9 Another example of a cluster of diseases sharing common risk factors is CAD, CKD, DM, AF and previous stroke. [27] [28] [29] These similar risk factors might be a good reason for the increase in the incidence of ED in AF patients.
Treatment of AF showed an improvement in hemodynamics that might reverse ED. 12 For instance, restoration of sinus rhythm after a cardioversion for an AF patient increases circulating endothelial progenitor cells and improves endothelial dysfunction. 30 However, there are some studies reporting that the use of phosphodiesterase inhibitors, U.S. Food and Drug Administration-approved medications to treat ED, is related to the occurrence of AF. 31, 32 Hahn et al. reported a patient with ED who developed AF after sildenafil intake, but the mechanism of AF was catecholamine excess secondary to a druginduced hypotensive effect. As long as the medication is used appropriately, phosphodiesterase inhibitor would be safe and very useful for this specific subgroup of patients. Vice versa, beta-blockers used as rate control medication in patients with AF are also known as ED-triggered medication through the non-selective beta receptor pathway. Some studies have shown that the use of most selective beta-1 receptor medication is appropriate for AF patients who are at risk of developing ED. 33 We also recommend using digoxin or calcium channel blocker as an alternative to beta-blockers to avoid the risk of ED.
The limitations of the present study are noteworthy. First, observational studies have a disadvantage regarding confounding factors. Second, most of the included studies explored prevalence rather than the association between ED and the onset of AF. However, the lack of evidence encourage researchers to look further into the relationship and management of ED in AF patients. AF should be strictly measured by, at least, 12-lead ECG, rather than ICD-9-CM. ED is also a subjective complaint that needs to be quantitatively defined by a standard questionnaire score, IIEF-5 questionnaire or SHIM questionnaire score. Qualitative assessment of ED might lead to either overestimating or underestimating the actual incidence. In addition, beta-blockers, which are widely used for rate control in AF, are also one of the established etiologies of ED. Data on beta-blockers was not provided in most of the literature we explored. Finally, this was a meta-analysis of observational studies. Thus, it can at best identify only associations between ED and AF, but not a causal relationship. In summary, the present study, to the best of our knowledge, reviewed the most up-to-date literature showing the far-fromperfect care that we, as healthcare providers, can use to fill that gap. Our study showed an association between ED and AF. Future well-designed studies are required on this issue.
